The unique structure and gene targets of the HDAC6 enzyme lends itself to specific inhibitors and several specific HDAC6 inhibitors have been developed as anti-cancer agents in clinical trials (clinicaltrials.gov NCT03008018, NCT02935790, NCT01323751). This evidence concerns the gene HDAC6 and cancer.